Phase 4 PTSD Trial, Recruiting NCT06573970 Sponsor: VA Office of Research and Development Condition: PTSD
Back to Ptsd

Phase 4 PTSD Trial, Recruiting

NCT06573970
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Military veterans between the ages of 18 and 75 who have both PTSD and Attention Deficit Disorder (ADHD), confirmed by specific symptom rating scores appropriate for their age group
  • People who are in good enough physical health to take part in the study
  • People who are able to understand the study and give their informed consent to participate

Who may not be able to join:

  • People younger than 18 or older than 75
  • People who are known to have a sensitivity or allergic reaction to the drug atomoxetine
  • People with certain health conditions that could be made worse by atomoxetine, including a specific type of eye pressure problem (narrow angle closure glaucoma), difficulty passing urine, high blood pressure, nerve or muscle movement disorders such as tics or Tourette's syndrome, or a history of epilepsy or seizures
  • People who have had a severe traumatic brain injury (though those with a mild traumatic brain injury may still be considered)
  • People currently taking certain medications that could interact with atomoxetine, including a class of antidepressants called MAOIs, blood pressure medications, or certain other antidepressants such as paroxetine, fluoxetine, or venlafaxine
  • People currently taking stimulant medications or certain other antidepressants, though those who stopped taking them at least two weeks before the trial starts may be considered
  • People currently receiving another treatment that is working well for them, though continued standard therapies may be allowed if PTSD symptoms remain severe enough to meet the study's requirements (confirm with trial site)
  • People with a current or past diagnosis of certain serious mental health conditions, including schizophrenia, schizoaffective disorder, psychotic disorders, or bipolar disorder (types I, II, or unspecified); depressive disorders linked to PTSD may be allowed
  • People who have had a significant alcohol, marijuana, or other drug use disorder in the past three months, though occasional or recreational use that does not meet the level of a diagnosed disorder may be considered on a case-by-case basis
  • People who are currently pregnant or planning to become pregnant during the trial period
  • People who are currently experiencing strong thoughts of suicide or harming others, or who have made a suicide attempt in the past three months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Zhewu Wang, MD, Ralph H. Johnson VA Medical Center, Charleston, SC

Phone: (843) 789-7949

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
29 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov